GlassScriptPhysician profile
Anand Bhuptani
NPI 1144200114
$50,468.33
in general payments reported to CMS, 2019-2025
40 companies · $214 in 2025
The $214 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,329 · 2020: $5,374 · 2021: $18K · 2022: $4,987 · 2023: $14K · 2024: $228 · 2025: $214.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $1,199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,000.00 |
| Food and Beverage | $1,198.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $34,859.34 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $4,986.51 | 2019-2025 | Ofev |
| Astrazeneca Pharmaceuticals LP | $3,675.63 | 2019-2022 | |
| Grifols USA, LLC | $2,434.60 | 2019-2022 | |
| Electromed, INC. | $690.90 | 2019-2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $572.08 | 2019-2024 | |
| Sunovion Pharmaceuticals INC. | $377.59 | 2019-2021 | |
| Genentech USA, INC. | $354.75 | 2019-2023 | Xolair |
| Harmony Biosciences LLC | $353.66 | 2020-2024 | Wakix |
| Janssen Pharmaceuticals, INC | $234.40 | 2019-2024 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $224.66 | 2020-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $176.39 | 2019-2021 | |
| Genzyme Corporation | $164.06 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $147.45 | 2019-2022 | |
| United Therapeutics Corporation | $113.73 | 2019-2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $111.98 | 2019-2025 | Dupixent |
| Advanced Respiratory, INC | $93.02 | 2019-2020 | |
| Pfizer INC. | $80.48 | 2019 | |
| Mylan Specialty L.P. | $76.43 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $72.06 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $70.36 | 2021-2022 | |
| Insmed, INC. | $56.61 | 2019-2025 | Brinsupri, Arikayce |
| Paratek Pharmaceuticals, INC. | $52.93 | 2019-2020 | |
| Shire North American Group INC | $51.66 | 2019 | |
| Philips North America LLC | $48.59 | 2019 | |
| Novartis Pharmaceuticals Corporation | $44.01 | 2019-2020 | |
| Pulmonx Corporation | $40.94 | 2024-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Zephyr Delivery Catheter |
| Inspire Medical Systems, INC. | $38.36 | 2023 | Inspire |
| Baxter Healthcare | $35.82 | 2023-2025 | Hillrom - Monarch Airway Clearance System, Hillrom - Life 2000 Ventilation System |
| Ucb, INC. | $33.89 | 2019 | |
| Mallinckrodt Hospital Products INC. | $30.47 | 2020 | |
| Arbor Pharmaceuticals, INC. | $30.21 | 2020 | |
| Sanofi-Aventis U.S. LLC | $27.30 | 2020-2021 | |
| Adma Biomanufacturing LLC | $18.29 | 2021 | |
| Ironshore Pharmaceuticals INC. | $17.67 | 2021 | |
| Merck Sharp & Dohme LLC | $15.47 | 2025 | Vaxneuvance, Capvaxive, Rotateq |
| Fisher & Paykel Healthcare INC | $15.04 | 2022 | |
| Resmed Corp | $14.37 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $13.48 | 2019 | |
| Gilead Sciences, INC. | $13.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anand Bhuptani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.